Therapy Detail

Therapy Name SSR128129E
Therapy Description

SSR128129E is an allosteric pan-FGFR inhibitor which may inhibit angiogenesis and tumor growth (PMID: 23597562, PMID: 24760775).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
SSR128129E FGFR Inhibitor (Pan) 18 SSR128129E is an allosteric pan-FGFR inhibitor which may inhibit angiogenesis and tumor growth (PMID: 23597562, PMID: 24760775).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable SSR128129E Preclinical - Cell line xenograft Actionable In a preclinical study, SSR128129E inhibited tumor growth in several solid tumor cell line xenograft models (PMID: 23597562). 23597562
FGFR3 wild-type myeloid neoplasm sensitive SSR128129E Preclinical Actionable In a preclinical study, SSR128129E inhibited proliferation of myeloma cells expressing wild-type FGFR3 in culture (PMID: 23597562). 23597562
FGFR3 K650E myeloid neoplasm no benefit SSR128129E Preclinical Actionable In a preclinical study, SSR128129E did not inhibit proliferation of myeloma cells expressing FGFR3 K650E in culture (PMID: 23597562). 23597562
Clinical Trial Phase Therapies Title Recruitment Status